With a revenue increase of 16.74% in the third quarter 2026, year on year to cumulative value of $5,013 million, Alnylam Pharmaceuticals Inc 's revenue per employee grew on a trailing twelve months basis to $ 2,005,297, this is below the company average. Within the Healthcare sector Employees of 43 other companies have achieved higher revenue per employee. While Alnylam Pharmaceuticals Inc 's total ranking has deteriorated compared to the previous quarter from 342 to 506. Alnylam Pharmaceuticals Inc has 2,500 employees.
Alnylam Pharmaceuticals Inc. recently presented additional data from the HELIOS-B clinical trial, highlighting the significant benefits of its drug, AMVUTTRA (vutrisiran), for patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The results indicate a marked reduction in both mortality and a variety of significant cardiovascular events among treated patients, underscoring the drug’s potential as a transformative therapy within this niche yet critical area of healthcare.AMVUTTRA, delivered via subcutaneous injection, works by silencing the production of transthyretin, the protein that aggregates and causes amyloid deposits detrimental to heart function. The pivotal results from HELIOS-B, presented at a recent Heart Failure Congress, not only reinforce AMVUTTRA’s efficacy but also highlight Alnylam Pharmaceuticals commitment to addressing severe unmet medical needs in patients grappling with ATTR amyloidosis.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
